Massimo R. Di Iorio

Long term anticoagulation for Catheter-Related deep vein thrombosis of the upper extremities in women with cancer: retrospective analysis of effectiveness and safety outcomes

Chiara Cavallaro, Paolo Santini, Laura Leoni, Carolina Mosoni et autres

Catheter-related upper extremity deep vein thrombosis (CRT-UEDVT) is a possible complication in patients with cancer carrying a central venous catheter. Anticoagulation is the primary treatment, but optimal duration is unclear. This study evaluated effectiveness and safety of different lengths of anticoagulation in …

it (code pays fourni par la source)

Abstract P3-07-03: Real-world comparison of safety and effectiveness of dose dense (2-weekly) versus weekly paclitaxel given with trastuzumab as neoadjuvant treatment in HER2-positive early stage breast cancer

Yael Berner-Wygoda, Eitan Amir, Chloe Perlon, Diego Malón et autres

Abstract Background: Traditionally, trastuzumab-based chemotherapy combinations used in HER2-positive early-stage breast cancer are delivered as 21-day cycles, either comprising weekly paclitaxel or 3-weekly docetaxel). In Ontario, Canada, an alternative dose-dense protocol allows the administration of 4 cycles of doxorubicin and cyclophosphamide (AC) …

Abstract P1-02-02: Indirect comparison of sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) in advanced breast cancer (aBC): safety and efficacy analysis

Neha Pathak, Sudhir Kumar, Yael Berner-Wygoda, Abhenil Mittal et autres

Abstract Background: SG and Dato-DXd are antibody drug conjugates (ADCs) used in aBC. Both target humanized anti-trophoblast cell-surface antigen 2 (TROP2) and both have a similar (irinotecan-based) payload. There are few comparative data on these drugs. Methods: We searched MEDLINE, as well …

Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis

Neha Pathak, Massimo R. Di Iorio, Diego Malon Gimenez, Yael Berner-Wygoda et autres

ca (code pays fourni par la source)

Continuing Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Advanced Breast Cancer: A Meta-Analysis

Neha Pathak, Sudhir Kumar, Diego Malón, Massimo R. Di Iorio et autres

Background: The use of cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i) with endocrine therapy (ET) is a first-line standard treatment for hormone receptor-positive (ER+) Human Epidermal Growth factor Receptor-2-negative (HER2-) advanced breast cancer. The data supporting incorporation of CDK 4/6i + ET beyond …

ca, in (code pays fourni par la source)

Safety and Effectiveness of Adriamycin and Cyclophosphamide Followed by Dose Dense (Every 2 Weeks) Paclitaxel Given With Trastuzumab as Neoadjuvant Treatment in HER2-Positive Early-Stage Breast Cancer

Yael Berner-Wygoda, Meredith Li, Chloe Perlon, Diego Malón et autres

ca (code pays fourni par la source)

Abstract PO4-04-09: Incidence, prevalence, risk factors, and impact of fatty liver disease in metastatic HR+/HER2− breast cancer patients treated with Endocrine Therapy and CDK 4/6 Inhibitor

Diego Malon Gimenez, Consolacion Molto Valiente, Shopnil Prasla, Danielle Cuthbert et autres

Abstract Background: In patients with early-stage breast cancer (BC), non-alcoholic fatty liver disease (NAFLD) is associated with increased recurrence, cardiovascular events, and non-cancer death. Endocrine therapy increases the risk of NAFLD. The impact of cyclin-dependent kinases 4/6 inhibitors (CDKi) combined with endocrine …

ca (code pays fourni par la source)

Abstract PO5-04-11: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) beyond progression in hormone receptor positive advanced breast cancer: a systematic review and meta-analysis

Neha Pathak, Sudhir Kumar, Diego Malon Gimenez, Massimo R. Di Iorio et autres

Abstract Introduction The use of CDK 4/6i (palbociclib/ribociclib/abemaciclib) with endocrine therapy (ET) is a widely adopted first line standard treatment for hormone receptor positive advanced breast cancer (HR+ABC). Data supporting incorporation of CDK 4/6i ± ET beyond progression are less clear. Recent …

ca, in (code pays fourni par la source)

High fiber diet to counteract early signs of heart damages: an ultrastructural morphological study to pioneer new strategies for management of cardiotoxicity in breast cancer

Francesca Arnaboldi, Nicoletta Gagliano, Mariela Módica, Alessandra Stacchiotti et autres

it (code pays fourni par la source)

Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials

Abhenil Mittal, Faris Tamimi, Consolación Moltó, Massimo R. Di Iorio et autres

Background: The absolute and relative benefits of adjuvant bisphosphonates on disease-free survival and overall survival in patients receiving contemporary systemic therapy for early breast cancer is uncertain. Methods: Data from randomized trials of adjuvant bisphosphonates that recruited patients exclusively after 2000 and …

ca (code pays fourni par la source)

Ophthalmic diseases in meningitis within the pediatric population

Jia You, Milad Modabber, Massimo R. Di Iorio, Daniela Toffoli

ca (code pays fourni par la source)

Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis

Abhenil Mittal, Consolacion Molto Valiente, Faris Tamimi, Massimo R. Di Iorio et autres

BACKGROUND: Presence of circulating tumor DNA (ctDNA) is prognostic in solid tumors treated with curative intent. Studies have evaluated ctDNA at specific "landmark" or multiple "surveillance" time points. However, variable results have led to uncertainty about its clinical validity. METHODS: A PubMed …

ca, jo (code pays fourni par la source)